tetano
Editor, Senior Moderator
Eur J Clin Invest. 2020 May 1:e13258. doi: 10.1111/eci.13258. [Epub ahead of print]
QTc Evaluation in COVID-19 patients treated with Chloroquine/Hydroxichloroquine.
Monzani A[SUP]1[/SUP], Genoni G[SUP]2[/SUP], Scopinaro A[SUP]3[/SUP], Pistis G[SUP]3[/SUP], Kozel D[SUP]3[/SUP], Secco GG[SUP]3[/SUP].
Author information
Abstract
In late December 2019, a cluster of pneumonia cases caused by a novel coronavirus occurred in Wuhan, China and has spread rapidly initially throughout Europe and later USA (1). The pathogen was originally called 2019 novel coronavirus (2019-nCoV) and later named severe acute respiratory syndrome coronavirus 2 (SARS-nCoV-2) by the World Health Organization (WHO).
This article is protected by copyright. All rights reserved.
PMID:32356580DOI:10.1111/eci.13258
QTc Evaluation in COVID-19 patients treated with Chloroquine/Hydroxichloroquine.
Monzani A[SUP]1[/SUP], Genoni G[SUP]2[/SUP], Scopinaro A[SUP]3[/SUP], Pistis G[SUP]3[/SUP], Kozel D[SUP]3[/SUP], Secco GG[SUP]3[/SUP].
Author information
Abstract
In late December 2019, a cluster of pneumonia cases caused by a novel coronavirus occurred in Wuhan, China and has spread rapidly initially throughout Europe and later USA (1). The pathogen was originally called 2019 novel coronavirus (2019-nCoV) and later named severe acute respiratory syndrome coronavirus 2 (SARS-nCoV-2) by the World Health Organization (WHO).
This article is protected by copyright. All rights reserved.
PMID:32356580DOI:10.1111/eci.13258